Fibromyalgia in men: comparison of psychological features with women.

Department of Medicine, University of Illinois College of Medicine at Peoria, One Illinois Drive, Peoria, IL 61605, USA.
The Journal of Rheumatology (Impact Factor: 3.17). 01/2005; 31(12):2464-7.
Source: PubMed

ABSTRACT To describe possible differences in psychological factors in men compared to women with fibromyalgia syndrome (FM).
Forty men and 160 women with FM were evaluated for anxiety, stress, and depression measured by ordinal scales and validated psychological instruments. Clinical and psychological variables were evaluated by a protocol.
Both men and women scored high in the psychological variables measured but the results were not significantly different between them.
There was no significant difference between men and women with FM in their psychological status.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To investigate whether milnacipran is safe and effective in improving cognitive function in patients with fibromyalgia. Method: Patients were randomly assigned to receive milnacipran or placebo for 6 weeks, followed by a 1-week washout and then crossover to the other arm for another 6 weeks. The overall trial lasted 13 weeks and was conducted between July 2011 and May 2013. Assessments were performed at each visit. Neurocognition was measured by the Brief Assessment of Cognition (BAC) and MATRICS. Pain was assessed by the visual analog scale (VAS) for pain. Global assessment of fibromyalgia symptoms was measured by the Fibromyalgia Impact Questionnaire (FIQ) and tender point examination. Depression was assessed by the Beck Depression Inventory (BDI). Fatigue was assessed by the Fatigue Severity Scale. Functional outcome was evaluated by the Health Assessment Questionnaire. The Clinical Global Impressions-Severity of Illness (CGI-S) and Improvement (CGI-I) scales and the Patients Clinical Global Impression of Change were used to measure the global impression of severity and improvement. Results: 26 subjects were screened, and 20 subjects completed the trial. The change in verbal memory (P = .001) and the composite T score (P = .044) of the BAC and the change in the attention-vigilance domain T score (P = .042) were significantly improved, but there were no differences between the drug and placebo groups. The changes in the CGI-S scores were not significant, but the changes in the Clinical Impression-Improvement (CGI-I) scores showed worsening in the placebo group at week 1 (P = .032), week 2 (P = .024), week 4 (P = .024), and week 6 (P = .60) compared to baseline. The change in FIQ scores was not significant. Conclusions: Milnacipran may have a potential role in the improvement of pain, disability, and mood. The effect of milnacipran on cognition in fibromyalgia needs further research. Trial Registration: identifier: NCT01829243.
    01/2013; 15(6). DOI:10.4088/PCC.13m01555
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the therapeutic effects of a manual therapy protocol for improving pain, function, pressure pain thresholds, quality of sleep, and depressive symptoms in women and men with fibromyalgia syndrome (FMS). Eighty-nine patients were randomly assigned to experimental or control group. The experimental group (24 female, 21 male) received 5 sessions of manual therapy and the control group (24 female, 21 male) did not receive any intervention. Pressure pain thresholds (PPT), pain, impact of FMS symptoms, quality of sleep and depressive symptoms were assessed in both groups at baseline and after 48-hours of the last intervention in the experimental group. The ANCOVA found significant Group* Time* Sex interactions for McGill PPI and CES-D (P<0.01) was also found: men exhibited a larger effect size for depressive symptoms than women whereas women exhibited a greater effect size than men in the McGill PPI. A significant Group* Time* Sex interaction for PPT over suboccipital, upper trapezius, supraspinatus, second rib, gluteal region and tibialis anterior muscle was also found: men included in the experimental group experienced significant greater improvements in PPT as compared to women with FMS in the experimental group. Manual therapy protocol was effective for improving pain intensity, widespread pressure pain sensitivity, impact of FMS symptoms, sleep quality and depressive symptoms. In addition, sex differences were observed in response to treatment: women and men get similar improvements in quality of sleep and tender point count, whereas women showed a greater reduction in pain and impact of FMS symptoms than men, but men reported higher decreases in depressive symptoms and pressure hypersensitivity than women.
    The Clinical journal of pain 11/2013; DOI:10.1097/AJP.0000000000000008 · 2.70 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Health differences between men and women are determined by biological differences although health services often contribute to gender inequalities. Very few studies that analyze gender differences have been made up to date in these patients. This study aims to analyze sociodemographic, clinical and psychosocial differences between men and women diagnosed with FM and to examine the differential impact of their symptoms on their usual activities, including work environment, and the response these patients obtain from the health care system. Material and methods A descriptive cross-sectional survey was carried out with all the patients diagnosed with FM in 2003 in three clinics rheumatology units of a university hospital in Spain. Results The sociodemographic characteristics were very similar in men and women. However, there was a greater proportion of men diagnosed with FM on sick leave, compared to women with the same diagnosis. Men had a worse perception of their health, a higher percentage of psychiatric history and current mental illness and more impact of the disease. Discussion This is one of the first studies in Spain examining the differences between men and women diagnosed with FM. The results obtained in this study corroborate that, as in other diseases, there are gender differences in the clinical and psychosocial characteristics of men and women diagnosed with FM.
    Revista Clínica Española 10/2007; 207(9):433-439. DOI:10.1157/13109832 · 1.31 Impact Factor